What's Happening?
Kardigan's blood pressure drug, tonlamarsen, has shown a clinically meaningful effect on blood pressure, despite mixed results in a Phase 2 trial. The trial, involving nearly 200 patients with uncontrolled hypertension, aimed to assess the drug's ability
to control blood pressure through the biomarker angiotensinogen (AGT). While tonlamarsen achieved a significant reduction in AGT levels, it did not show a difference in systolic blood pressure between single and multiple dose groups. Despite this, Kardigan plans to advance the drug to a Phase 2b trial for patients with acute severe hypertension post-hospitalization.
Why It's Important?
The advancement of tonlamarsen into further trials underscores the ongoing efforts to address hypertension, a major public health issue in the U.S. The drug's potential to manage blood pressure in patients with severe hypertension could fill a critical gap in treatment options, particularly for those who do not respond well to existing therapies. This development highlights the importance of continued innovation in cardiovascular treatments and the potential for new therapies to improve patient outcomes.
What's Next?
Kardigan plans to conduct a Phase 2b trial focusing on patients with acute severe hypertension, which could provide more definitive data on the drug's efficacy and safety. The company will likely continue to analyze patient subgroups to identify those who may benefit most from tonlamarsen. The results of these trials could influence future treatment guidelines and potentially lead to broader use of the drug in clinical practice.
